| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Institute of Nutritional Science, Department of Pathophysiology of Human Nutrition, University of Bonn, Germany (YL, RP-L, and KP), and Merck Eprova AG, Schaffhausen, Switzerland (RM).
Background: Increased plasma total homocysteine (tHcy) is a risk factor for vascular disease and adverse pregnancy outcomes. Health authorities recommend periconceptional supplementation with 400 µg folic acid to prevent neural tube defects. Several countries have implemented food fortification with folic acid. However, excessive intake of folic acid could mask an undiagnosed vitamin B-12 deficiency. The biologically active [6S]-5-methyltetrahydrofolate ([6S]-5-MTHF) may be an alternative to folic acid because it is unlikely to mask vitamin B-12 deficiency symptoms.
Objective: We compared the tHcy-lowering potential of 2 dosages of [6S]-5-MTHF with that of 400 µg folic acid during 24 wk of supplementation.
Design: In this double-blind, randomized, controlled intervention trial, 144 female participants were supplemented daily with 400 µg folic acid, 416 µg [6S]-5-MTHF, 208 µg [6S]-5-MTHF, or placebo. Concentrations of tHcy and plasma folate were measured at baseline and at 4-wk intervals.
Results: After supplementation, there was a significant interaction between time and treatment with respect to changes in tHcy and plasma folate (both P < 0.001 by two-factor repeated-measures analysis of variance). The decrease in tHcy did not differ significantly between the 3 supplemented groups (P > 0.05; Tukey’s post hoc test). The increase in plasma folate in the group receiving 208 µg [6S]-5-MTHF was significantly lower than that in the groups receiving 400 µg folic acid (P < 0.001) or 416 µg [6S]-5-MTHF (P < 0.05).
Conclusions: [6S]-5-MTHF was shown to be an adequate alternative to folic acid in reducing tHcy concentrations. Supplementation with 416 µg [6S]-5-MTHF was no more effective than that with 208 µg [6S]-5-MTHF.
Key Words: [6S]-5-methyltetrahydrofolate • folic acid • homocysteine • plasma folate • long-term effect • supplementation • healthy women
This article has been cited by other articles:
|
|
 |
|
  E. P Quinlivan and J. F Gregory III Reassessing folic acid consumption patterns in the United States (1999 2004): potential effect on neural tube defects and overexposure to folate Am. J. Clinical Nutrition, December 1, 2007; 86(6): 1773 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Pietrzik, Y. Lamers, S. Bramswig, and R. Prinz-Langenohl Calculation of red blood cell folate steady state conditions and elimination kinetics after daily supplementation with various folate forms and doses in women of childbearing age Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1414 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Verwei, A. P. Freidig, R. Havenaar, and J. P. Groten Predicted Serum Folate Concentrations Based on In Vitro Studies and Kinetic Modeling are Consistent with Measured Folate Concentrations in Humans J. Nutr., December 1, 2006; 136(12): 3074 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lamers, R. Prinz-Langenohl, S. Bramswig, and K. Pietrzik Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age Am. J. Clinical Nutrition, July 1, 2006; 84(1): 156 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A Houghton, K. L Sherwood, R. Pawlosky, S. Ito, and D. L O'Connor [6S]-5-Methyltetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 842 - 850. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
